流感疫苗接种与心血管死亡及住院的关联:一项动态系统综述与前瞻性Meta分析
该动态系统综述与前瞻性Meta分析纳入6项随机对照试验(12,662人)和37项观察性研究(6,311,703人),评估流感疫苗对全因/心血管死亡及住院的影响。随机对照试验显示疫苗与全因住院风险降低显著相关(RR 0.86),但对全因死亡、心血管死亡及心血管住院无显著关联;观察性研究提示更强保护关联。
要点
- 随机对照试验中流感疫苗与全因住院风险降低显著相关(RR 0.86,95%CI 0.76-0.97)。
- 随机对照试验未显示疫苗与全因死亡、心血管死亡或心血管住院显著相关。
- 观察性研究提示流感疫苗与多数结局有更强保护关联,但心血管住院除外。
核心结论
- 观察性研究提示流感疫苗接种可能与较低的全因死亡、心血管死亡和全因住院相关,但随机对照试验仅显示全因住院风险降低,未提供明确证据支持对死亡或心血管住院的预防效果。
研究设计与样本
- 动态系统综述与前瞻性Meta分析,检索1994至2023年发表的随机对照试验和观察性研究,遵循PRISMA指南提取资料,采用Cochrane工具评估偏倚风险,按研究设计和心血管病史分层分析,使用GRADE系统评价证据质量,于2022年7月至10月进行随机效应模型Meta分析。
- 纳入6项随机对照试验共12,662名参与者(平均年龄62岁;45%女性;8,797例有既往心血管病)和37项观察性研究共6,311,703名参与者(平均年龄49岁;50%女性;1,189,955例有既往心血管病)。
- 仅纳入偏倚风险低危的随机对照试验,排除偏倚风险高于中危的观察性研究。
主要发现
- 随机对照试验中,流感疫苗与全因死亡(RR 0.85;95%CI 0.61-1.17)、心血管死亡(RR 0.80;95%CI 0.60-1.07)和心血管住院(RR 0.69;95%CI 0.47-1.02)无显著关联。
- 随机对照试验中观察到全因住院显著降低(RR 0.86;95%CI 0.76-0.97)。
- 全因住院的证据等级为中等,其他结局的证据等级为低。
- 观察性研究总体提示流感疫苗接种与结局之间有更强的保护关联,但心血管住院除外。
- 基于随机对照试验,一般人群与既往心血管病人群在全因死亡上的疫苗效果无差异,但汇总点估计仅在既往心血管病人群中倾向于获益。
关键数值与推荐
- 随机对照试验:全因死亡RR 0.85(95%CI 0.61-1.17);心血管死亡RR 0.80(95%CI 0.60-1.07);心血管住院RR 0.69(95%CI 0.47-1.02);全因住院RR 0.86(95%CI 0.76-0.97)。
- GRADE证据等级:全因住院为中等,其他结局为低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effects of seasonal influenza vaccination on cardiovascular disease (CVD) outcomes, including among individuals with established CVD, are uncertain. METHODS: To evaluate the efficacy and safety of influenza vaccines compared to no vaccines or placebo for preventing all-cause/CVD mortality or all-cause/CVD hospitalization in the general population and in populations with pre-existing CVD, we conducted a living systematic review (LSR) and prospective meta-analysis (PMA). Published randomized controlled trials (RCT) and observational studies between 1994 and 2023 were searched. PRISMA guidelines were followed in the extraction of study details, and risk of bias was assessed using the Cochrane tools. Analyses were stratified by study design and CVD history. Study quality was evaluated using GRADE system. Meta analyses based on random-effects models were performed between July and October 2022. Pooled risk ratios (RRs) for all-cause/CVD mortality and all-cause/CVD hospitalization were main outcomes. RESULTS: Six published RCTs comprising 12,662 participants (mean age, 62 years; 45 % women; 8,797 with pre-existing CVD) and 37 observational studies comprising 6,311,703 participants (mean age, 49 years; 50 % women; 1,189,955 with pre-existing CVD) were included. Only those RCTs judged to be low risk were included in the analyses, and observational studies at anything greater than moderate risk of bias were excluded. In RCTs, influenza vaccine was not significantly associated with lower all-cause mortality (RR, 0.85; 95 %CI, 0.61-1.17), cardiovascular death (RR, 0.80; 95 %CI, 0.60-1.07), or CVD hospitalization (RR, 0.69; 95 %CI, 0.47-1.02). A statistically significant reduction in all-cause hospitalization (RR, 0.86; 95 %CI, 0.76-0.97) was observed. The evidence level was assessed as moderate for all-cause hospitalization, and low for other outcomes. Overall, observational studies suggested a stronger protective association between influenza vaccination and outcomes, except for CVD hospitalization. Based on RCTs, there was no difference in the effects of influenza vaccination on all-cause mortality among the general population compared to those with pre-existing CVD, although the summary point estimate favored benefits only in those with pre-existing CVD. CONCLUSIONS: While observational studies suggest that influenza vaccination may be associated with lower all-cause and CVD mortality and all-cause hospitalization, RCTs reported to date suggest a reduction in the risk of all-cause hospitalization but do not provide clear evidence to support preventive effects on mortality (all-cause or CVD) or CVD hospitalization.
引用
- Liu R, Fan Y, Patel A, et al. The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis. Vaccine. 2024. PMID: 38267331. doi:10.1016/j.vaccine.2024.01.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。